Table 2. . Cases of immunotherapy-induced hypophysitis.

Case number	1	2	3	4	5	6
Age	70	70	64	77	46	24
Gender (M/F)	M	F	M	M	M	F
Immunotherapy	Ipilimumab	Ipilimumab	Ipilimumab	Ipilimumab	Ipilimumab	Pembrolizumab
Treatment dose (mg/kg)	3	3	3	3	3	2
Number of cycles prior to event	3	4	4	2	3	35
Hormonal defect (time of diagnosis)	Corticotroph, thyrotroph, gonadotroph	Corticotroph, thyrotroph	Corticotroph, gonadotroph	Corticotroph, thyrotroph, gonadotroph	Corticotroph, thyrotroph	Corticotroph, primary hypothyroidism
MRI findings	No abnormalities	No abnormalities	Not performed	No abnormalities	Not performed	Not performed
Symptoms	Headache, syncope	Nausea	Tiredness	Headache	Asymptomatic	Nausea, vomiting
Dexamethasone dose (mg)	16	8	8	10	Not given	Not given
Recovery from event	No	No	Yes	No	Yes	No
Hormone replacement (at the end of follow-up)	Levothyroxine, testosterone, hydrocortisone	Hydrocortisone, levothyroxine	None	Hydrocortisone, levothyroxine	None	Hydrocortisone, levothyroxine
Additional IMAEs	None	Rash	None	Rash	None	None

F: Female; IMAE: Immune mediated adverse event; M: Male; MRI: Magnetic resonance imaging.